Cargando…

Dipeptidyl peptidase-4 and kidney fibrosis in diabetes

Diabetic nephropathy (DN) is the most common cause of end-stage kidney disease worldwide and is associated with increased morbidity and mortality in patients with both type 1 and type 2 diabetes. Recent evidence revealed that dipeptidyl peptidase-4 (DPP-4) inhibitors may exhibit a protective effect...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shi, Sen, Koya, Daisuke, Kanasaki, Keizo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4752740/ https://www.ncbi.nlm.nih.gov/pubmed/26877767 http://dx.doi.org/10.1186/s13069-016-0038-0

Ejemplares similares

Dipeptidyl peptidase-4 plays a pathogenic role in BSA-induced kidney injury in diabetic mice
por: Takagaki, Yuta, et al.
Publicado: (2019)

The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2018)

Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin
por: Kanasaki, Keizo
Publicado: (2019)

Inhibition of Dipeptidyl Peptidase-4 Activates Autophagy to Promote Survival of Breast Cancer Cells via the mTOR/HIF-1α Pathway
por: Kawakita, Emi, et al.
Publicado: (2023)

Effect of switching to teneligliptin from other dipeptidyl peptidase‐4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease
por: Kitada, Munehiro, et al.
Publicado: (2018)

Three ileus cases associated with the use of dipeptidyl peptidase‐4 inhibitors in diabetic patients
por: Kanasaki, Keizo, et al.
Publicado: (2013)

MicroRNAs in Kidney Fibrosis and Diabetic Nephropathy: Roles on EMT and EndMT
por: Srivastava, Swayam Prakash, et al.
Publicado: (2013)

Deficiency in Dipeptidyl Peptidase-4 Promotes Chemoresistance Through the CXCL12/CXCR4/mTOR/TGFβ Signaling Pathway in Breast Cancer Cells
por: Li, Shaolan, et al.
Publicado: (2020)

Diabetic nephropathy: the role of inflammation in fibroblast activation and kidney fibrosis
por: Kanasaki, Keizo, et al.
Publicado: (2013)

Cancer biology in diabetes
por: Sen, Shi, et al.
Publicado: (2014)

N-acetyl-seryl-aspartyl-lysyl-proline Inhibits Diabetes-Associated Kidney Fibrosis and Endothelial-Mesenchymal Transition
por: Nagai, Takako, et al.
Publicado: (2014)

Lipid mediators in diabetic nephropathy
por: Srivastava, Swayam Prakash, et al.
Publicado: (2014)

Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
por: Daza-Arnedo, Rodrigo, et al.
Publicado: (2021)

The Role of Dipeptidyl Peptidase – 4 Inhibitors in Diabetic Kidney Disease
por: Panchapakesan, Usha, et al.
Publicado: (2015)

CD26/DPP-4: Type 2 Diabetes Drug Target with Potential Influence on Cancer Biology
por: Kawakita, Emi, et al.
Publicado: (2021)

Effect of Antifibrotic MicroRNAs Crosstalk on the Action of N-acetyl-seryl-aspartyl-lysyl-proline in Diabetes-related Kidney Fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2016)

N-acetyl-seryl-aspartyl-lysyl-proline: a valuable endogenous anti-fibrotic peptide for combating kidney fibrosis in diabetes
por: Kanasaki, Keizo, et al.
Publicado: (2014)

Interactions among Long Non-Coding RNAs and microRNAs Influence Disease Phenotype in Diabetes and Diabetic Kidney Disease
por: Srivastava, Swayam Prakash, et al.
Publicado: (2021)

The Nonglycemic Actions of Dipeptidyl Peptidase-4 Inhibitors
por: Kim, Na-Hyung, et al.
Publicado: (2014)

SIRT3 deficiency leads to induction of abnormal glycolysis in diabetic kidney with fibrosis
por: Srivastava, Swayam Prakash, et al.
Publicado: (2018)

Dipeptidyl peptidase‐4 inhibitors and sulfonylureas for type 2 diabetes: Friend or foe?
por: Yabe, Daisuke, et al.
Publicado: (2014)

Diabetic angiopathy and angiogenic defects
por: Xu, Ling, et al.
Publicado: (2012)

Serum and Adipose Dipeptidyl Peptidase 4 in Cardiovascular Surgery Patients: Influence of Dipeptidyl Peptidase 4 Inhibitors
por: Shibasaki, Ikuko, et al.
Publicado: (2022)

Dipeptidyl peptidase 4 inhibitors: Applications in innate immunity?
por: Yazbeck, R., et al.
Publicado: (2021)

Role of Dipeptidyl Peptidase 4 Inhibitors in Antidiabetic Treatment
por: Yin, Ruili, et al.
Publicado: (2022)

Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes
por: Richter, Bernd, et al.
Publicado: (2008)

Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
por: Capuano, Annalisa, et al.
Publicado: (2013)

Role of dipeptidyl peptidase-4 inhibitors in new-onset diabetes after transplantation
por: Lim, Sun Woo, et al.
Publicado: (2015)

N‐acetyl‐seryl‐aspartyl‐lysyl‐proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects
por: Kanasaki, Keizo
Publicado: (2020)

Biology of Obesity: Lessons from Animal Models of Obesity
por: Kanasaki, Keizo, et al.
Publicado: (2011)

Dipeptidyl peptidase-4 inhibitors: Novel mechanism of actions
por: Singh, Awadhesh Kumar
Publicado: (2014)

The PKM2 activator TEPP‐46 suppresses kidney fibrosis via inhibition of the EMT program and aberrant glycolysis associated with suppression of HIF‐1α accumulation
por: Liu, Haijie, et al.
Publicado: (2020)

Inhibition of Angiotensin-Converting Enzyme Ameliorates Renal Fibrosis by Mitigating DPP-4 Level and Restoring Antifibrotic MicroRNAs
por: Srivastava, Swayam Prakash, et al.
Publicado: (2020)

Dipeptidyl Peptidase 4: A New Link between Diabetes Mellitus and Atherosclerosis?
por: da Silva Júnior, Wellington Santana, et al.
Publicado: (2015)

Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19
por: Chen, Chun-Fan, et al.
Publicado: (2020)

New insights into the role of dipeptidyl peptidase 8 and dipeptidyl peptidase 9 and their inhibitors
por: Cui, Chenkai, et al.
Publicado: (2022)

Linagliptin ameliorated cardiac fibrosis and restored cardiomyocyte structure in diabetic mice associated with the suppression of necroptosis
por: Adhikari, Juthi, et al.
Publicado: (2023)

Oral Administration of N-Acetyl-seryl-aspartyl-lysyl-proline Ameliorates Kidney Disease in Both Type 1 and Type 2 Diabetic Mice via a Therapeutic Regimen
por: Nitta, Kyoko, et al.
Publicado: (2016)

The use of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes & chronic kidney disease
por: Bittle, Polly A.
Publicado: (2017)

Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy
por: Cox, Mary Elizabeth, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_9jjg9545vgo3jpkbdr5n1olgav